Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

HGS to use Dyax technology to screen for peptides

Executive Summary

Dyax will apply its phage display method of drug discovery in a collaboration to identify and optimize leads for Human Genome Sciences' therapeutic targets. Dyax may also use its phage--viruses that attack bacteria and can be engineered to express peptides--to develop high-throughput screens for HGS and to purify its development candidates and drugs.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
    • Large Molecule
    • Large Molecule
      • Antibodies
  • In Vitro Diagnostics
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Contract

Related Companies

Advertisement
UsernamePublicRestriction

Register